The p53 protein is redox-sensitive in vitro but in vivo effectors of this sensitivity are not known. In yeasts deficient for thioredoxin (Trx) reductase (TRR), p53 accumulates in an inactive, oxidized form, suggesting a role for TRR-Trx in controlling p53. In mammalian cells, p53 binds to redox factor-1 (APE/Ref-1), an enzyme containing an abasic endonuclease domain involved in base excision repair, and a thiol reductase domain recycled by Trx and involved in regulating the transcription factor AP-1. To evaluate the role of TRR and APE/Ref-1 in p53 regulation, we have abrogated their expression using RNA interference in cell lines expressing wild-type p53. Inhibition of TRR resulted in accumulation of oxidized Trx and increased levels and DNA-binding activity of p53, with no phosphorylation of Ser15 or Ser20. In contrast, inhibition of APE/Ref-1 accelerated p53 protein turnover, resulting in a decrease in p53 levels and activity. However, inhibition of either TRR or APE/Ref-1 did not prevent activation and accumulation of p53 in response to DNAdamage by doxorubicin. When both factors were inhibited, basal levels of p53 were restored. These results suggest that TRR-Trx and APE/Ref-1 cooperate in the control of basal p53 activity, but not in its induction by DNAdamage.
Introduction
The tumour suppressor protein p53 is a transcription factor controlling cell cycle progression, cell survival, and DNA repair in cells exposed to genotoxic stress (Hainaut and Hollstein, 2000) . This factor is constitutively expressed in a latent form in most cells and tissues. Exposure to DNA-damage induces p53 to accumulate in the nucleus in an active form with high affinity for specific DNA sequences, after post-translational modifications at both N and C terminus of the protein (Pluquet and Hainaut, 2001) . Activated p53 regulates the transcription of several sets of target genes, including effectors of the cell cycle (p21/WAF1/Cip1, 14-3-3s, GADD45), of apoptosis (Bax1, KILLER/DR5, CD95/APO-1/FAS, AIP1), and of DNA repair (p53R2). p53 also represses the expression of NOS2 and COX2 and modulates transcription, replication, and DNA repair through interaction with proteins such as RP-A and components of TFIID and TFIIH complexes (Hainaut and Hollstein, 2000; Vousden and Lu, 2002; Fei and El Deiry, 2003; Hofseth et al., 2004) . Sitespecific DNA binding by p53 depends upon a highly conserved DNA-binding domain that contains a zinc ion, coordinated on cysteines and histidine residues (Cho et al., 1994; Hainaut and Mann, 2001 ). Mutation of these residues markedly decreases sequence-specific DNA binding activity in vitro (Rainwater et al., 1995) . Agents such as dithiotreitol (DTT) and metal chelators modulate the DNA binding of p53 in vitro and in intact cells (Hainaut and Milner, 1993a, b; Pavletich et al., 1993) , and the metal-binding protein metallothionein may act as a cofactor in the control of DNA-binding activity (Meplan et al., 2000) . These observations have raised the hypothesis that p53 belongs to a family of redox-dependent transcription factors, with functional similarities to NF-kB or AP-1. This hypothesis has received further support from studies performed in yeast by Pearson and Merrill (1998) , who have shown that yeasts deficient for thioredoxin (Trx) reductase (TRR) activity accumulated p53 in a transcriptionally inactive form, and from the work of Ueno et al. (1999) , who have shown that Trx regulates the activation of WAF1 by p53 (Ueno et al., 1999) .
Trx is a small, ubiquitous, multifunctional protein with a redox-active disulfide/dithiol within its active site sequence (-Cys-Gly-Pro-Cys-) (Arner and Holmgren, 2000) . Trx operates together with TRR, an NADPHdependent, FAD-containing enzyme, as a protein disulfide-reducing system. Mammalian Trx is a stressinducible protein which can be secreted from cell and was originally cloned as a growth factor produced by leukemia virus type I (Tagaya et al., 1989) . Trx plays complex roles in maintaining cellular homeostasis in response to oxidative stress. Several forms of stress (UVA, UVB, hydrogen peroxide) induce Trx to translocate from cytoplasm to nucleus, preventing DNA-damage (Hirota et al., 1997) . In addition, Trx is involved in the regulation of redox-sensitive transcription factors containing critical cysteines in their DNA-binding domains, including NF-kB (Freemerman et al., 1999) , the glucocorticoid receptor (Makino et al., 1999) , AP-1 (Hirota et al., 1997; Freemerman et al., 1999) , and p53 (Ueno et al., 1999) . Trx is also responsible for the recycling of redox factor-1 (APE/ Ref-1), an ubiquitous nuclear protein (Hirota et al., 1997) . APE/Ref-1, also known as HAP-1, is a bifunctional enzyme with two separate catalytic domains, one containing a thiol reductase activity and the other an apurinic/apyrimidinic (AP) endonuclease (Xanthoudakis et al., 1994) . It acts as the second major enzymatic step in base excision repair (BER), the first being the elimination of damaged bases by DNA glycosylase to produce AP sites. APE/Ref-1 nicks the phosphodiester backbone 5 0 to the AP site. In short-patch BER, DNA polymerase b excises the 5 0 deoxyribose phosphate moiety remaining after incision by APE/Ref-1 and inserts one or two nucleotides before specific DNA ligases seal the nick. Long-patch repair involves the displacement of three to eight bases surrounding the AP site and resynthesis of the corresponding nucleotides by DNA polymerases b, d, or e (Fritz et al., 2003) . The bifunctional nature of APE/Ref-1 is highly conserved from plant to man, with the exception of the yeast homologue, which lacks the redox-active domain (Kelley et al., 2003) . This domain makes APE/Ref-1 inducible by oxidative stress but also exerts apparently independent activities in the reduction of critical cysteines in the DNA-binding domain of the transcription factor AP-1 (Evans et al., 2000) .
Two lines of experimental evidence link p53 with APE/Ref-1. First, APE/Ref-1 binds to p53, enhances DNA binding in vitro through redox-dependent and independent mechanisms, and works as an activator of p53 transactivation in intact cells (Jayaraman et al., 1997; Gaiddon et al., 1999) . Second, p53 plays complex roles in the regulation of basal and stress-induced BER. Stimulation of BER by p53 is correlated with its capacity to interact directly both with APE/Ref-1 and with DNA polymerase b (Offer et al., 2001; Zhou et al., 2001; Zurer et al., 2004) . In this study, we have sought to clarify the role of the Trx/TRR pathway and of APE/ Ref-1 in the control of p53 levels and activity in response or not to genotoxic stress.
Results

Silencing of TRR induces oxidation of Trx and accumulation of p53
Studies in Saccharomyces cerevisiae lacking the TRR1 gene have shown that reporter gene transactivation by human p53 is compromised through a mechanism that involves accumulation of the p53 protein in an oxidized form (Pearson and Merrill, 1998) . To determine whether downregulation of TRR may also impair p53 activity in human cells, we used short inhibitory RNA (siRNA) to interfere with expression of TRR1, the main (cytoplasmic) form of TRR, in the breast cancer cell line MCF-7 that expresses wild-type p53 protein. Transfection of TRR-targeted siRNAs led to a specific downregulation of TRR mRNA and protein, with a decrease of over 90% in protein levels at 48 h after transfection ( Figure 1a and data not shown), with no significant effect on cell viability at 72 h. To determine whether inhibition of TRR results in a significant decrease in TRR activity, the oxidation status of Trx was analysed by protein electromobility shift electrophoresis after alkylation of reactive sulfhydryls (Figure 1b) . Inhibition of TRR induced a clear mobility shift in Trx, similar to the one observed after treatment of cells with high concentrations of the thiol-oxidizing agent diamide. However, measurement of intracellular levels of reactive oxygen species (ROS) using the fluorescent probe 2 0 ,7 0 -dichlorofluoresceine diacetate (DCF-DA) did not detect any significant increase in the levels of free radicals (data not shown). Next, we analysed the protein levels and DNA-binding activity of p53 after TRR silencing in two human cancer cell lines (MCF-7, HCT116) and one noncancer cell line (WI38 diploid fibroblasts) expressing wild-type p53. In all cell lines, inhibition of TRR led to p53 protein accumulation and increased DNA-binding activity, detectable at 48 h after transfection (corresponding to the time point when the silencing of TRR reaches a maximum) (Figures 2a and b) . The extent of accumulation and the increase in DNA-binding activity were similar to those observed after exposure of cells for 3 h to doxorubicin at 1 mg/ml. There was no increase in levels of oxidized forms of p53, as detected by protein electromobility shift electrophoresis after alkylation of reactive sulfhydryls (Figure 2c ). Figure 2d shows the effect of TRR silencing on the subcellular localization of p53 and Trx in MCF-7 cells. In cells transfected with scrambled siRNA, p53 was found to be present in both the cytoplasm and the nucleus of most cells, a small proportion of them showing dominant cytoplasmic staining. In contrast, Trx was essentially nuclear. After silencing of TRR, there was a clear nuclear accumulation of p53 and a cytoplasmic sequestration of Trx.
To evaluate the effect of p53 activation after TRR silencing in MCF-7 cells, we analysed the expression of a set of well-known p53-target genes by semiquantitative reverse transcription-polymerase chain reaction (Figure 3) . First, TRR inhibition did not alter p53 mRNA levels. Second, TRR inhibition led to increased expression of MDM2, p21WAF1, GADD45, and 14-3-3s, but not of PIG3 and BAX. This is in contrast with treatment with doxorubicin, which did not induce a detectable increase of 14-3-3s mRNA, but induced the expression of PIG3.
We next determined whether TRR silencing could induce p53 stabilization and post-translational modification in a manner similar to that observed in response to DNA-damaging agents. Using cycloheximide to block p53 protein synthesis in MCF-7 cells, we found that p53 had a slower turnover in cells transfected with the TRR siRNA, with over 50% of the protein still detectable after 90 min (as compared to a half-life of less than 30 min in cells transfected with a control, scrambled siRNA) (Figure 4a ). Imunoprecipitation with anti-Mdm2 antibodies showed a detectable decrease in (Figure 4b ). However, TRR silencing did not induce the phosphorylation of p53 on Ser15 and Ser20, some typical post-translational modifications mediated by DNA-damage signalling kinases such as ATM and checkpoint kinase-2 (Chk-2), and observed after exposure of cells to many DNA-damaging agents ( Figure 4c ). Overall, these results indicate that TRR silencing results in the stabilization, accumulation, and activation of p53. This is in contrast with experiments in the yeast, which have shown inactivation of p53 through oxidation of cysteines in TRR-deficient mutants. On the other hand, activation of p53 after TRR silencing in human cells is not accompanied by the same posttranslational changes as those induced by oxidative stress.
Silencing of TRR does not affect p53 induction and activation in response to doxorubicin
We next examined whether TRR silencing had an effect on the rate and time course of p53 activation in response to genotoxic stress. Cells were treated with doxorubicin at 48 h after transfection with siRNA and the levels of p53 protein and DNA-binding activity were monitored 4 h after treatment. Figure 5 shows that, after silencing of TRR, the p53 protein accumulated in response to doxorubicin to essentially similar levels as in control cells transfected by a scrambled siRNA. The accumulation was correlated with increased phosphorylation of Ser15 and increased DNA-binding activity. However, since p53 levels and DNA-binding activity were already markedly enhanced upon silencing of TRR, the foldinduction in response to doxorubicin appears to be reduced. Furthermore, cell cycle analysis did not show any significant increase in doxorubicin-induced cell death in cells with silenced TRR (data not shown). Thus, inhibition of TRR does not prevent p53 protein activation, suggesting that TRR and Trx oxidation status do not play important roles in the control of p53 protein activation in response to genotoxic stress.
APE/Ref-1 is involved in the basal control of p53 by TRR-Trx
In TRR-deficient yeasts, p53 inactivation has been shown to result from biochemical alteration of p53 by Total protein extracts were immunoprecipitated (IP) with antibody to Mdm2, and immunoprecipitates were analysed by Western blot with anti-p53 antibody. As control, precipitation beads were used in the absence of a specific antibody ('beads'). The band detected in this condition corresponds to a nonspecific signal. Total protein extracts were also used to determine Mdm2 protein levels. Detection of actin was used as a loading control. (c) MCF-7 cells were transfected with scramble or anti-TRR siRNA for 48 h or treated with doxorubicin (4 h) as a positive control. Nuclear protein extracts were used for Western blot analysis of the phosphorylation status of p53 on serine 15 and 20 using monoclonal antibodies. Detection of Ku80 was used as a loading control cysteine oxidation due to accumulation of oxidized Trx. Since this phenomenon was not observed in human cells, we reasoned that, in the latter system, the interaction of Trx with p53 may be indirect and involve one or several other proteins. Figure 7c , we analysed the co-precipitation of p53 with APE/Ref-1 after TRR silencing. We found that both proteins could form complexes in control cells in basal conditions, and that the levels of these complexes were increased over 30-fold in response to doxorubicin. After TRR silencing, however, levels of complexes detected in basal conditions were barely modified but the increase induced after treatment with doxorubicin was modest (threefold), 10 times less than in control cells. These results suggest that APE/Ref-1 is required for both p53 protein 
Discussion
Redox regulation is critical for the function of a number of transcription factors. The p53 protein has the structural and biochemical properties of a redoxregulated transcription factor. First, the DNA-binding activity of p53 towards synthetic consensus sequences is stimulated in vitro by thiol-reducing agents (Hainaut and Milner, 1993a; Pavletich et al., 1993) . Second, reduction of thiols modulates the conformation of the . (e) Nuclear extracts as described in (d) were analysed for p53 DNA-binding activity using TRANSAM kit
Redox regulation of p53 basal activity S Seemann and P Hainaut central domain of the protein (Hainaut and Milner, 1993b) . Third, in a yeast experimental system, there is evidence that deletion of TRR downregulates p53 activity by locking the protein into an oxidized form (Merrill et al., 1999; Merwin et al., 2002) . Fourth, in human cells, overexpression of thioredoxin increases p53 transactivation capacity towards reporter genes (Ueno et al., 1999) . Fifth, the p53 protein interacts in vitro and in intact cells with APE/Ref-1, which contains a Trx-dependent thiol reductase activity, also involved in the control of AP-1, another redox-dependent transcription factor (Hirota et al., 1997; Jayaraman et al., 1997; Gaiddon et al., 1999) . However, although there is pharmacological evidence that thiol-reducing agents can modulate p53 protein activity in intact cells, the role of redox regulation in the physiological control of p53 activity is poorly understood. Exposure of cells to oxidizing agents does not inhibit p53, but rather activates the protein through DNA-damage-dependent pathways. Moreover, there is no clear evidence that the p53 protein undergoes direct, redox-dependent modifications during the process of p53 induction by DNAdamage signals.
In this study, we have used RNA interference as a tool to examine the involvement of TRR and APE/Ref-1 in the control of p53 protein activity in cancer and noncancer cell lines. This approach has allowed us to examine the consequence of expression silencing on the activity of endogenous, wild-type p53. We show that silencing of TRR increases the basal level of wild-type p53, but not the overall level of p53 after exposure of cells to DNA-damaging agents. Under these conditions, inhibition of TRR in MCF-7 cells locked Trx in an oxidized form that was sequestered into the cytoplasm. In contrast, p53 was redirected and accumulated into the nucleus. Although p53 is mostly a nuclear protein, regulation of nuclear shuttling is thought to be an integral part of the regulation of p53 function (Fabbro and Henderson, 2003) . In MCF-7, the particular pattern of p53 localization in nonstressed cells, as well as the predominant nuclear localization after expopure to DNAdamage, have been described previously (Takahashi and Suzuki, 1993) . Thus, the accumulation of p53 in the nucleus provides good evidence that TRR silencing indeed triggers a p53 activation process.
Conceivably, silencing of TRR could result into global, intracellular oxidizing stress and in formation of DNA strand break damage. However, we did not detect any significant increase in intracellular levels of free radicals or in DNA strand breaks formation after silencing of TRR, and the accumulation of p53 was not associated with phosphorylation of the protein on N-terminal sites commonly modified in response to DNA-damage. Alternatively, oxidation of p53 may lead to its accumulation as a degradation-resistant, altered protein. However, silencing of TRR did not modify the reactivity of p53 with conformation-specific antibodies PAb1620 and PAb240 (data not shown) and there was no detectable change in the status of reactive p53 thiols. Moreover, the accumulated protein was functional, as indicated by increased DNA-binding activity and increased transactivation of a set of p53 target genes, with some selectivity towards genes involved in cell cycle control as compared with the genes activated after accumulation of p53 to comparable levels in response to the DNA-damaging agent doxorubicin. Thus, silencing of TRR and modulation of intracellular distribution of Trx seems to contribute to enhance p53 protein activation by increasing p53 levels and by facilitating its accumulation into the nucleus.
Previous studies addressing the role of thioredoxin in the regulation of p53 have used different approaches. Ueno et al. (1999) have shown that overexpression of Trx increased the activity of transfected wild-type p53 towards a luciferase reporter controlled by a segment of the WAF1 promoter containing a p53-binding site (Ueno et al., 1999) . This effect was not detected when a redox-inactive mutant Trx (in which cysteines 32 and 35 within the active site were mutated to serines) was transfected together with wild-type Trx. However, transfection of mutant Trx alone did not affect the activity of transfected p53, suggesting that on its own, this mutant does not modulate p53 function but rather prevents wild-type, redox-active Trx to exert an effect. This observation is compatible with our data in suggesting that it is the redox activity of Trx that matters in the modulation of p53 function. The results presented here suggest that this modulation is exerted by oxidized, rather than reduced Trx.
In S. cerevisiae lacking TRR, Merwin et al. (2002) found that accumulation of oxidized Trx induced, in turn, the accumulation of p53 in an oxidized, inactive form. Double inactivation of TRR and Trx restored p53 reduced status and transcriptional activity . These results are in contrast with our observations in mammalian cells, where silencing of TRR and oxidation of Trx did induce p53 activation. It is possible that, in mammalian cells, nuclear exclusion of oxidized Trx prevents significant oxidization of the DNA-binding competent form of p53. Another explanation is that, in mammalian cells, additional factors are involved as intermediate in mediating the effects of oxidized Trx on p53. Although we have found that p53 can co-precipitate with Trx in human cells, two-hybrid experiments in yeasts using human p53 and Trx do not provide evidence for a direct, stable interaction between the two proteins (data not shown). Interestingly, the yeast homologue of APE/Ref-1 differs from the mammalian enzyme by the absence of a domain that contains the thiol reductase activity, localized in the N-terminus of the mammalian protein (Kelley et al., 2003) . Thus, it is possible that APE/Ref-1 may work in mammalian cells as a transducer of Trx-dependent redox effects. Previous studies have shown that APE/ Ref-1 modulates p53 function through two distinct mechanisms: as a protein binding in the C-terminus of p53 and activating its DNA-binding capacity, and as a thiol-reducing factor that facilitates DNA binding without forming stable interactions with p53 in vitro (Jayaraman et al., 1997; Gaiddon et al., 1999) . In our experiments, the p53 protein was barely detectable in basal conditions after silencing of APE/Ref-1, and its activation in response to stress was partially prevented. In parallel, the levels of p53 complexes with Mdm2 were increased, suggesting that downregulation of APE/Ref-1 increased p53 degradation through an Mdm2-dependent pathway. This observation suggests that APE/Ref-1 plays an important role in maintaining basal p53 levels and is also involved in its control in response to genotoxic insult. This interpretation is compatible with the results of Gaiddon et al. (1999) , who showed that an antisense mRNA that partially blocked the expression of APE/Ref-1 downregulated the capacity of transfected wild-type p53 to induce apoptosis (Gaiddon et al., 1999) . Moreover, in our experiments, when both APE/Ref-1 and TRR were simultaneously silenced, the basal levels of p53 as well as the induced levels after exposure to doxorubicin were similar to those observed in cells transfected with scrambled siRNA. In addition, the levels of immunoprecipitated complexes containing p53 and Trx showed a marked decrease after silencing of APE/Ref-1. We interpret these observations to suggest that APE/Ref-1 is required as an intermediate for oxidized Trx to modulate p53 activity.
Both APE/Ref-1 and Trx have been shown to play contrasted roles in the regulation of redox-dependent transcription factors. In the case of AP-1, the DNA binding of Fos-Jun heterodimers is stimulated in vitro by APE/Ref-1 , and Wei et al. (2000) showed that Trx interacted with APE/Ref-1 to mediate activation in response to ionizing radiation (IR) (Wei et al., 2000) . Furthermore, constitutive overexpression of a form of TRR with the active cysteine motif deleted resulted in the absence of induction of AP-1 activity or reporter gene expression in response to IR (Wei et al., 2000) . In the case of NF-kB, no direct involvement of APE/Ref-1 has been demonstrated, but Trx has been shown to play distinct roles in the cytoplasm and in the nucleus. In the cytoplasm, wild-type Trx prevents the degradation of IkB and acts as a suppressor of NF-kB activation, probably through scavenging reactive oxygen species that work as signalling molecules in the pathway of NF-kB activation . In contrast, in the nucleus, Trx acts as an activator of NFkB DNA binding and transactivation, probably through the reduction of a critical cysteine in the DNA-binding domain (Matthews et al., 1992; Freemerman et al., 1999; Hirota et al., 1999; Hirota et al., 2001) . The results presented here suggest that the same components also act as cofactors to control p53 activity. Basically, Trx and APE/Ref-1 appears to be involved in at least three overlapping aspects of the regulation of transcription factors: DNA binding, nuclear translocation, and protein stabilization. In the case of AP-1, the role of Trx (in complex with APE/Ref-1) appears to be limited to the control of DNA binding. In the case of NF-kB, Trx appears to be involved both in the control of DNA binding and nuclear translocation. Overall, our results and those of Prives and co-workers (Jayaraman et al., 1997; Gaiddon et al., 1999) suggest that, in the case of p53, the Trx-APE/Ref-1 connection works in the control of DNA binding, nuclear translocation, and protein stability.
In normal, physiological conditions, AP sites occur at a rate of about 10 000 sites per cell per day (Lindahl and Nyberg, 1972) . Thus, cells should be equipped with a control system to distinguish between various contexts of DNA-damage and prevent untimely, overactivation of p53. First, p53 can modulate the activity of gycosylases involved in the initial step of BER. Two different mechanisms have been reported. In the case of 3-methyladenine (3-MeAde) DNA glycosylase, p53 trans-represses the glycosylase activity, decreasing the formation of AP sites (Zurer et al., 2004) . In the case of human 8-oxoguanine glycosylase 1 (hOGG1), p53 forms direct protein complexes and enhances the removal of 8-oxoG from damaged DNA (Achanta and Huang, 2004) . Second, p53 stimulates BER by stabilizing the interactions between DNA polymerase b and abasic DNA. In human and murine cells, basal BER activity closely parallels the levels of p53, and is much reduced in cell extracts immunodepleted of p53 (Zhou et al., 2001) .
Overall, our results indicate that the redox sensitivity of p53 goes far beyond simple modulation of disulfide status and may provide an extremely sensitive connection between p53 activity and the sensing and repair of DNA-damage.
Materials and methods
Cell culture
The human breast carcinoma cell line MCF-7 cells was routinely cultured in DMEM medium (GibcoBRL) under an atmosphere of 5% CO 2 . HCT116 colon carcinoma cells were cultured in McCoy's 5A medium under an atmosphere of 10% CO 2 . These two cell lines (obtained from Pr Puisieux) were cultured in presence of 10% heated foetal calf serum. WI38 human foetal pulmonary fibroblasts (obtained from Dr M Oren) were grown in MEM medium containing 20% of nonheated foetal calf serum. All cells were maintained at 371C in media containing 2 mM glutamine and 0.5% penicillinstreptomycin (Sigma). Cells were treated with drugs at 50-65% confluency. Treatments with H 2 O 2 and doxorubicin were performed at concentrations with no significant short-term effect on cell viability, to avoid interference of toxicity in evoking the observed effects. . After 48 h, the cells were treated with 1 m/ml doxorubicin (Sigma) for various times. Cells were harvested, and RNAs or proteins were extracted for subsequent analysis.
RNA interference assay
Protein extracts
For total protein extraction, cells double washed in PBS were collected by scraping in 100 ml (per million cells) RIPA-like buffer (50 mM Tris pH 7.4, 250 mM NaCl, 0.1% SDS, 2 mM DTT, 0.5% NP40, and protease inhibitors: 0.5 mM PMSF, 0.5 mg/ml leupeptine, 2 mg/ml aprotinin, and 0.7 mg/ml pepstatin, Sigma). After 30 min incubation on ice, protein fractions were collected by a 15 min centrifugation at 15 000 g and 41C.
For nuclear protein extraction, control and treated cells were washed twice with ice-cold phosphate-buffered saline (PBS) and collected by scraping. Nuclear extracts were prepared as described in Verhaegh et al. (1997) . Briefly, cells were lysed for 15 min on ice in 100 ml (per million cells) extraction buffer-A (20 mM HEPES pH 7.6, 20% glycerol, 10 mM NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, 20 mM NA 3 VO 4 , 1 mM DTT, 0.1% NP40), containing protease inhibitors (as described above). After centrifugation at 300 g and 41C for 4 min, cytosolic fraction was collected and stored at À801C. Nuclei were lysed for 30 min on ice in 50 ml (per million cells) extraction buffer-B (buffer A with 0.5 M instead of 10 mM NaCl) and then centrifuged for 15 min at 15 000 g and 41C. The soluble nuclear proteins fraction was recovered and stored at À801C. Nuclear extracts were used for evaluation of p53 DNA-binding activity using a TransAMt p53 ELISA kit as described by the manufacturer (Active Motif).
Western blot
For detection by Western blot, all fractions were assayed for proteins content according to Bradford (1976) . Equal amounts of proteins were mixed with Laemmli sample buffer, resolved on 10 or 15% SDS-polyacrylamide gels, and transferred to PVDF membranes (Roche). For human p53 detection, the first antibody used was DO-7 (DAKO) at 250 ng/ml; for detection of p53 phosphorylated on residues 15 and 20, the rabbit Phospho-p53 (Ser15) and (Ser20) antibodies (referred 9284 and 9287, respectively, Cell Signalling Technology) at 1/750 dilution were used. For Trx detection, a mouse anti-Trx antibody (2G11/Trx, BD Pharmingen) was used at 1/1500 dilution. For TRR detection, the first antibody was a goat anti-TRR antibody (sc-18220, Santa Cruz Biotechnology) at 1/1000 dilution, and for APE/Ref-1 detection, membranes were blotted with a mouse anti-Ref-1 antibody (clone 15, BD Transduction Laboratories) at 1/1000 dilution. Mdm2 protein was detected with a mouse antibody (IF2, Calbiochem) at 1/1000 dilution. All proteins were revealed with secondary peroxidase-conjugated antibodies, raised against mouse, rabbit, or goat Igs (at 1/10 000, 1/3000 or 1/10 000 dilutions, respectively) and enhanced chemiluminescence (ECL, Amersham Pharmacia Biotech). Equal loading of proteins were monitored by looking at the levels of the nuclear Ku80 protein 
RT-PCR
Total RNA was extracted from cells with Trizol (Gibco-BRL) and 2 mg of RNA were used for RT. The cDNA corresponding to the gene of interest was then amplified. PCR products were analysed on a 1% agarose gel with ethidium bromide. Protein electrophoretic mobility shift assay
Protein redox status was determined as described previously (Bersani et al., 2002) . Briefly, cells were lysed in a buffer containing 8 M urea, 100 mM Tris (pH8.2), 1 mM EDTA, and 30 mM iodoacetatic acid to methylate free, reduced thiols. Reduction of protein disulfides is then achieved with 3.5 mM DTT. After reduction, newly generated thiols are amidomethylated with 10 mM iodoacetamide. The proteins are then fractionated on urea-polyacrylamide gels (for Trx: 9%; for p53: 6%), blotted onto PVDF membrane and detected with the anti-p53 DO-7 monoclonal antibody or the anti-Trx monoclonal antibody as described above. Presence of amidomethyl groups decreases the mobility of the protein, allowing separation of oxidized from reduced forms.
Indirect immunofluorescence labelling
For immunofluorescence, MCF-7 cells were rinsed in PBS, fixed with 4% paraformaldehyde in PBS and permeabilized by treatment with 0.1% Triton for 5 min. Then, nonspecific sites were blocked with BSA 1% in PBS overnight at 41C, and cells were subsequently incubated with p53 (CM-1, Novocastra, diluted 1/100) or Trx (IMCO Corp., diluted 1/200) antibodies for 1 h at room temperature. Cells were subsequently flooded by anti-rabbit (Jackson Immunoresearch) or anti-goat (sc-2349 Santa Cruz) rhodamine-conjugated IgG, respectively (dilution 1/200), for 45 min in the dark. Nuclei were stained with DAPI for 5 min, and specimens were mounted in Vectashield, observed under Axioplan2 microscope (Zeiss) and pictures were acquired with a Quantixt camera (Photomoetrics).
Abbreviations ATM, ataxia telangiectasia mutated; APE/Ref-1, redox factor-1; BER, base excision repair; Chk-2, checkpoint kinase-2; DTT, dithiothreitol; IR, ionizing radiation; RNAi, RNA interference; ROS, reactive oxygen species; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis; siRNA, short inhibitory RNA; TRR, thioredoxin reductase; Trx, thioredoxin; UVA/UVB, ultraviolet A (320-400 nm) or B (290-320 nm).
